Skip Navigation


ToxSci Advance Access originally published online on February 27, 2008
Toxicological Sciences 2008 103(2):260-267; doi:10.1093/toxsci/kfn043
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
103/2/260    most recent
kfn043v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Marx-Stoelting, P.
Right arrow Articles by Schwarz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marx-Stoelting, P.
Right arrow Articles by Schwarz, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Tumor Promotion in Liver of Mice with a Conditional Cx26 Knockout

Philip Marx-Stoelting*, Johanna Mahr*, Thomas Knorpp{dagger}, Sandra Schreiber*, Markus F. Templin{dagger}, Thomas Ott{ddagger}, Albrecht Buchmann* and Michael Schwarz*,1

* Institute of Pharmacology and Toxicology, Department of Toxicology, University of Tübingen, Wilhelmstr. 56, 72074 Tübingen, Germany {dagger} NMI, Markwiesenstr. 55, 72770 Reutlingen, Germany {ddagger} IZKF/Central Unit for Transgenic Animals, Ottfried-Mueller-Str. 27, 72076 Tübingen, Germany

1 To whom correspondence should be addressed at Institute for Pharmacology and Toxicology, Wilhelmstr. 56, 72074 Tübingen, Germany. Fax: +49-7071-29-2273. E-mail: michael.schwarz{at}uni-tuebingen.de.

Received January 21, 2008; accepted February 19, 2008


  Abstract

Connexin (Cx) 26 and 32 are the major gap junction proteins in liver. We recently demonstrated that Cx32 is essential for phenobarbital (PB)–mediated tumor promotion in mouse liver. To investigate whether Cx26 plays a similar role, an initiation-promotion experiment was conducted using mice with a liver-specific knockout of Cx26. Control and Cx26-deficient mice were injected a single dose of N-nitrosodiethylamine (DEN, 90 µg/g b.wt.) at 6 weeks of age and groups of mice were subsequently kept on a PB (0.05%) containing or control diet for 35 weeks. At the end of the experiment, the carcinogenic response in the liver was monitored. Mice from PB treatment groups showed strongly increased liver weights compared with mice treated with DEN alone, which was mostly due to a much higher tumor burden. The tumor response in PB-treated mice of both strains was quite similar, but the number of smaller tumors and of enzyme-altered neoplastic lesions was somewhat larger in PB-treated Cx26 knockout (Cx26 KO) compared with wild-type mice, whereas the volume fraction of enzyme-altered lesions was slightly reduced in PB-treated Cx26-deficient mice. There was no significant difference in tumor prevalence between Cx26 KO and wild-type mice. Altogether our present data show that elimination of Cx26 has only minor effects on chemically induced mouse hepatocarcinogenesis, in striking contrast to the effects seen in Cx32 KO mice.

Key Words: connexin; liver; phenobarbital; tumor promotion; β-catenin.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.